Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:INO
- CUSIP: N/A
- Web: www.inovio.com
Capitalization:- Market Cap: $535.4 million
- Outstanding Shares: 90,134,000
Average Prices:- 50 Day Moving Avg: $7.60
- 200 Day Moving Avg: $6.91
- 52 Week Range: $5.50 - $11.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.05
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $37.63 million
- Price / Sales: 13.20
- Book Value: $1.42 per share
- Price / Book: 3.88
Profitability:- EBIDTA: ($80,300,000.00)
- Net Margins: -235.91%
- Return on Equity: -65.97%
- Return on Assets: -48.95%
Debt:- Current Ratio: 2.67%
- Quick Ratio: 2.67%
Misc:- Average Volume: 1.95 million shs.
- Beta: 2.85
- Short Ratio: 7.34
Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.31) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.31). The firm earned $10.40 million during the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The business's revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.11) EPS. View Inovio Pharmaceuticals' Earnings History.
Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?
9 analysts have issued twelve-month price targets for Inovio Pharmaceuticals' stock. Their forecasts range from $11.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $22.11 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.
What are analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/11/2017)
- 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Genus plc (GNS), Immunomedics (IMMU), Albany Molecular Research (AMRI), Heron Therapeutics (HRTX), Cellectis S.A. (CLLS), Biohaven Pharmaceutical Holding Co Ltd (BHVN), TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA), Enanta Pharmaceuticals (ENTA), CRISPR THERAPTC (CRSP), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), Intellia Therapeutics (NTLA), Mesoblast Limited (MESO), WAVE Life Sciences (WVE), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN) and Agenus (AGEN).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
- Peter D. Kies, Chief Financial Officer
- Niranjan Y. Sardesai Ph.D., Chief Operating Officer
- Mark L. Bagarazzi M.D., Chief Medical Officer
- Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
- George W. Bickerstaff III, Director
- David B. Weiner, Director
- Simon X. Benito, Independent Director
- Angel Cabrera Ph.D., Independent Director
Who owns Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Round Table Services LLC (0.17%), Russell Investments Group Ltd. (0.07%), Private Capital Advisors Inc. (0.05%), ING Groep NV (0.02%) and First Financial Bank Trust Division (0.02%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including ING Groep NV and Russell Investments Group Ltd.. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include David B Weiner, Jong Joseph Kim and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.
Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins, Niranjan Sardesai and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.
How do I buy Inovio Pharmaceuticals stock?
Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $5.51.
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.78) |
| Consensus Price Target: | $22.11 (301.29% upside) |
Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | HC Wainwright | Set Price Target | Buy | $13.00 | High |  |
| 7/18/2017 | Aegis | Reiterated Rating | Buy | $14.00 | Low | |
| 6/8/2017 | Maxim Group | Set Price Target | Buy | $12.00 | High | |
| 6/8/2017 | Piper Jaffray Companies | Upgrade | Neutral -> Overweight | $14.00 | Medium | |
| 5/25/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $11.00 | High | |
| 5/1/2017 | Nomura | Reiterated Rating | Buy | $40.00 | Low | |
| 5/1/2017 | Jefferies Group LLC | Reiterated Rating | Neutral | $38.00 | Low | |
| 5/1/2017 | BNP Paribas | Reiterated Rating | Neutral | $39.00 | Low | |
| 10/4/2016 | Brean Capital | Initiated Coverage | Buy | $18.00 | N/A | |
| 6/21/2016 | Rodman & Renshaw | Reiterated Rating | Buy | $17.00 | N/A | |
(Data available from 7/28/2015 forward)
Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | ($0.31) | ($0.31) | $5.83 million | $10.40 million | View | N/A | |
| 3/15/2017 | Q4 2016 | ($0.29) | ($0.35) | $5.21 million | $8.50 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.26) | ($0.28) | $5.16 million | $12.54 million | View | Listen | |
| 8/8/2016 | Q2 | ($0.21) | ($0.26) | $4.95 million | $6.20 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.14) | ($0.11) | $4.75 million | $8.10 million | View | N/A | |
| 3/14/2016 | Q4 | ($0.20) | ($0.25) | $6.96 million | $5.94 million | View | Listen | |
| 11/9/2015 | Q3 | $0.04 | $0.07 | $1.84 million | $24.18 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.13) | ($0.10) | $5.52 million | $5.30 million | View | Listen | |
| 5/11/2015 | Q1 | ($0.11) | ($0.18) | $7.04 million | $5.20 million | View | Listen | |
| 3/16/2015 | Q414 | ($0.10) | ($0.12) | $5.24 million | $2.50 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.11) | ($0.12) | $5.60 million | $1.80 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.17) | ($0.19) | $1.80 million | $3.80 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.04) | ($0.05) | $1.41 million | $2.40 million | View | N/A | |
| 3/17/2014 | Q413 | ($0.03) | ($0.04) | $1.36 million | $1.70 million | View | N/A | |
| 11/11/2013 | Q3 | ($0.02) | ($0.16) | $2.99 million | $9.50 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.05) | ($0.05) | $2.07 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)Current Year EPS Consensus Estimate: $-1.05 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS
Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 27.77%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | David B Weiner | Director | Sell | 8,000 | $8.00 | $64,000.00 | |
| 3/31/2017 | Jong Joseph Kim | CEO | Sell | 147,180 | $6.54 | $962,557.20 | |
| 3/27/2017 | Morton Collins | Director | Buy | 21,300 | $6.25 | $133,125.00 | |
| 8/29/2016 | Niranjan Sardesai | COO | Sell | 21,800 | $9.30 | $202,740.00 | |
| 6/28/2016 | Morton Collins | Director | Buy | 10,000 | $9.13 | $91,300.00 | |
| 5/18/2016 | Simon X Benito | Director | Sell | 6,250 | $10.37 | $64,812.50 | |
| 4/15/2016 | Morton Collins | Director | Buy | 68,400 | $9.52 | $651,168.00 | |
| 9/30/2015 | Niranjan Sardesai | COO | Buy | 4,000 | $5.50 | $22,000.00 | |
| 8/14/2015 | Simon X Benito | Director | Buy | 6,000 | $7.21 | $43,260.00 | |
| 4/13/2015 | Angel Cabrera | Director | Buy | 8,000 | $9.53 | $76,240.00 | |
| 10/9/2014 | Peter Kies | CFO | Buy | 3,960 | $10.10 | $39,996.00 | |
| 8/21/2014 | Morton Collins | Director | Buy | 8,000 | $10.01 | $80,080.00 | |
| 8/20/2014 | Morton Collins | Director | Buy | 40,600 | $9.74 | $395,444.00 | |
| 8/12/2014 | Jong Joseph Kim | CEO | Buy | 250,000 | $9.06 | $2,265,000.00 | |
| 8/12/2014 | Niranjan Sardesai | COO | Buy | 2,550 | $8.70 | $22,185.00 | |
| 4/15/2014 | Jong Joseph Kim | CEO | Buy | 25,000 | $2.25 | $56,250.00 | |
| 11/13/2013 | Morton Collins | Director | Buy | 254,500 | $1.82 | $463,190.00 | |
| 4/16/2013 | Mark Bagarazzi | Insider | Buy | 60,000 | $0.56 | $33,600.00 | |
| 4/2/2013 | Jong Joseph Kim | CEO | Buy | 90,000 | $0.50 | $45,000.00 | |
| 3/22/2013 | Angel Cabrera | Director | Buy | 40,000 | $0.54 | $21,600.00 | |
| 3/20/2013 | Jong Joseph Kim | CEO | Buy | 60,000 | $0.53 | $31,800.00 | |
| 3/20/2013 | Niranjan Sardesai | COO | Buy | 25,000 | $0.53 | $13,250.00 | |
| 1/15/2013 | Morton Collins | Director | Buy | 100,000 | $0.67 | $67,000.00 | |
| 11/14/2012 | Austin W & Greenhouse Da Marxe | Major Shareholder | Sell | 622,550 | $0.53 | $329,951.50 | |
| 8/15/2012 | Angel Cabrera | Director | Buy | 75,000 | $0.59 | $44,250.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
| Source: |
|
| Date | Headline |
|---|
 | Inovio Pharmaceuticals to Report Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - July 28 at 3:47 AM |
 | Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given a $13.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 27 at 10:34 AM |
 | Inovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017 - GlobeNewswire (press release)
globenewswire.com - July 26 at 8:09 PM |
 | Inovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 26 at 8:09 PM |
| Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : July 20, 2017
finance.yahoo.com - July 21 at 9:03 PM |
 | Montco immunotherapy company prices $75M stock sale - Philadelphia Business Journal
www.bizjournals.com - July 20 at 11:43 PM |
 | Biotech Movers: Sarepta, Inovio, Mylan - TheStreet.com
www.thestreet.com - July 20 at 11:43 PM |
 | Why MarineMax, Inovio Pharmaceuticals, and Check Point Software Technologies Slumped Today - Motley Fool
www.fool.com - July 20 at 11:43 PM |
| BUZZ-US STOCKS ON THE MOVE- IBM, Vertex Pharma, WW Grainger, Scripps Networks, Morgan Stanley - Nasdaq
www.nasdaq.com - July 20 at 3:17 AM |
| Inovio Announces Pricing of Public Offering of Common Stock - Nasdaq
www.nasdaq.com - July 20 at 3:17 AM |
| Here's Why Inovio Pharmaceuticals, Inc. Stock Fell Today - Motley Fool
www.fool.com - July 20 at 3:17 AM |
 | BRIEF-Inovio Pharmaceuticals says co has about $92 mln of cash and cash equivalents and short-term investments - SEC Filing
www.reuters.com - July 19 at 10:15 PM |
| Today's Research Reports on Trending Tickers: Inovio Pharmaceuticals Inc. and Universal Display Corporation
finance.yahoo.com - July 19 at 10:15 PM |
| Biotech Movers: Vertex Continues to Move on Data for CF Regimen
finance.yahoo.com - July 19 at 10:15 PM |
| Here's Why Inovio Pharmaceuticals, Inc. Stock Fell Today
finance.yahoo.com - July 19 at 10:15 PM |
| Inovio Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - July 19 at 10:15 PM |
| Inovio Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - July 19 at 7:04 AM |
| Inovio Pharmaceuticals' (NASDAQ:INO) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - July 18 at 1:19 PM |
 | Inovio Pharmaceuticals, Inc. - StreetInsider.com
www.streetinsider.com - July 16 at 11:57 AM |
| Inovio Pharmaceuticals, Inc. (INO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:52 PM |
| Inovio Pharmaceuticals, Inc. (INO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 8:31 PM |
| Biotech Movers: Exelixis, Omeros, Inovio
finance.yahoo.com - July 10 at 7:53 PM |
| Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT Set at $13.00 by HC Wainwright
www.americanbankingnews.com - July 7 at 6:56 PM |
 | Inovio's Monoclonal Antibody Platform Achieves Proof-of-Principle Validation
www.rttnews.com - July 7 at 6:28 AM |
| Inovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
finance.yahoo.com - July 7 at 6:28 AM |
| Brokerages Anticipate Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 6 at 12:32 AM |
| Brokerages Anticipate Inovio Pharmaceuticals, Inc. (INO) to Announce -$0.19 Earnings Per Share
www.americanbankingnews.com - July 6 at 12:32 AM |
 | Prostate Specific Antigen Pipeline Therapeutics Development Review H1 2017 Says a New Research Report at RnRMarketResearch.com
www.prnewswire.com - June 22 at 11:12 PM |
| Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - Nasdaq
www.nasdaq.com - June 21 at 3:37 PM |
| Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - GlobeNewswire (press release)
globenewswire.com - June 20 at 2:57 AM |
| Inovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
finance.yahoo.com - June 19 at 12:21 PM |
| Inovio Pharma (INO) Completes Enrollment for Second Zika Vaccine Phase 1 Trial with 160 Subjects in Puerto Rico
www.streetinsider.com - June 16 at 5:27 AM |
| Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
finance.yahoo.com - June 16 at 5:26 AM |
| Why Is Inovio (INO) Up 21.3% Since the Last Earnings Report?
finance.yahoo.com - June 14 at 11:22 AM |
| Inovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 13 at 8:52 PM |
| 3 Stocks That Could Put Amazon's Returns to Shame
finance.yahoo.com - June 13 at 5:41 PM |
| Maxim Group Analysts Give Inovio Pharmaceuticals Inc (INO) a $12.00 Price Target
www.americanbankingnews.com - June 11 at 8:30 AM |
| $18.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter
www.americanbankingnews.com - June 11 at 7:44 AM |
| Inovio Pharmaceuticals Inc (INO) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - June 10 at 12:28 AM |
| Cramer’s Exec Cut: CEOs examine the power of strategic pa...
finance.yahoo.com - June 9 at 8:24 PM |
| Inovio Pharmaceuticals Inc (INO) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - June 9 at 7:38 PM |
| Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises
finance.yahoo.com - June 9 at 9:32 AM |
 | FDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study - Benzinga
www.benzinga.com - June 8 at 11:58 PM |
| Why Inovio Pharmaceuticals, Inc. Is Rising Today - Motley Fool
www.fool.com - June 8 at 11:58 PM |
| Inovio Pharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - June 8 at 11:58 PM |
| Biotech Movers: NewLink, Inovio, Juno
finance.yahoo.com - June 8 at 6:52 PM |
| Why Inovio Pharmaceuticals, Inc. Is Rising Today
finance.yahoo.com - June 8 at 6:52 PM |
| Inovio Pharmaceuticals Inc (INO) Upgraded to Overweight by Piper Jaffray Companies
www.americanbankingnews.com - June 8 at 12:22 PM |
| FDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study
feeds.benzinga.com - June 8 at 11:46 AM |
| Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
finance.yahoo.com - June 8 at 6:07 AM |
Inovio Pharmaceuticals (INO) Chart for Friday, July, 28, 2017
